Key result
Both lacidipine and enalapril prevented left ventricular hypertrophy in spontaneously hypertensive rats, but only lacidipine significantly decreased cardiomyocyte size and single-cell contractility.
Why the study?
Does lacidipine compared to enalapril improve left ventricular cardiomyocyte remodeling in spontaneously hypertensive rats?
Does lacidipine compared to enalapril improve left ventricular cardiomyocyte remodeling in spontaneously hypertensive rats?
Lacidipine, but not enalapril, significantly decreases cardiomyocyte size and single-cell contractility in spontaneously hypertensive rats, despite both preventing overall left ventricular hypertrophy.
Hypothesis-generating for lacidipine-specific cardiomyocyte effects beyond LVH prevention; leaves open clinical translation pending human studies.
Antihypertensive medications are the most efficient drugs in achieving regression of myocardial hypertrophy in both clinical studies and animal models of hypertension. Nevertheless, there is a lack of clear and concise comparative study of their effects on the modulation of cardiomyocyte morphology and function. Here, we assessed the tissue-protective actions of 2 of these drugs, the calcium channel blocker lacidipine (3 mg/kg/day) and the angiotensin-converting enzyme-inhibitor enalapril (10 mg/kg/day) in vivo, after 8 weeks of treatment of 12-week-old spontaneously hypertensive rats, as well as in vitro, after short-term (4 min) application to isolated cardiomyocytes. Left ventricular hypertrophy (LVH) was compared at organ, tissue, and single-cell level. Our data showed that both drugs prevented the LVH of 20-week-old spontaneously hypertensive rats, but only lacidipine significantly decreased the cardiomyocyte size. Similarly, the single-cell contractility was significantly lowered in lacidipine-treated rats only. The effect of lacidipine was initiated shortly after exposure to the drug in a dose-dependent manner at 0.5 Hz, as well as at 2 Hz, with EC(50) of 10(-7) mol/L. These results can help in understanding the effects of these drugs on the prevention of LVH.
No takes yet. Share an insight, caveat, or question.
Cagalinec et al. (2006) studied Hypertension and Left Ventricular Hypertrophy. Lacidipine vs. Enalapril (10 mg/kg/day) was evaluated on Left ventricular hypertrophy and cardiomyocyte size/contractility. Both lacidipine and enalapril prevented left ventricular hypertrophy in spontaneously hypertensive rats, but only lacidipine significantly decreased cardiomyocyte size and single-cell contractility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: